

VPA10387/084/001

VANGUARD CPV-L.

Variation	Summary	Date
Vet - F.I.a.1 d)	VRA-S - Vet - F.I.a.1 d) - d) The change relates to a biological/immunological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - F.I.a.1 d) - Quality Changes - Active Substance - Manufacture - Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - The change relates to a biological/immunological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product	29/01/24
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	19/06/23
B.II.d.2.c	II - B.II.d.2.c - c) Substantial change to, or replacement of, a biological/ immunological/ immunochemical test method or a method using a biological reagent or replacement of a biological reference preparation not covered by an approved protocol - B.II.d.2.c - QUALITY CHANGES - FINISHED PRODUCT - Control of finished product - Change in test procedure for the finished product - Substantial change to, or replacement of, a biological/ immunological/ immunochemical test method or a method using a biological reagent or replacement of a biological reference preparation not covered by an approved protocol	28/09/22
B.II.b.3.b	II - B.II.b.3.b - b) Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product - B.II.b.3.b - QUALITY CHANGES - FINISHED PRODUCT - Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product -	28/09/22

	Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product	
--	--	--